(Q39852481)

15 September 2017

Development, validation, and clinical implementation of an assay to measure total antibody response to naglazyme (galsulfase) (English)

1 reference

15 September 2017

1

Joleen T White

1 reference

15 September 2017

Lisa Argento Martell

2

1 reference

15 September 2017

Andrea Van Tuyl

3

1 reference

15 September 2017

Ryan Boyer

4

1 reference

15 September 2017

Laura Warness

5

1 reference

15 September 2017

Gary T Taniguchi

6

1 reference

15 September 2017

Erik Foehr

7

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

15 September 2017

1 reference

15 September 2017

10

1 reference

15 September 2017

2

1 reference

15 September 2017

363-372

1 reference

https://scigraph.springernature.com/pub.10.1208/s12248-008-9043-6

15 September 2017

0 references

cites work

Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-ac

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Replacement therapy in Mucopolysaccharidosis type VI: advantages of early onset of therapy.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2751393

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18607760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18607760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18607760

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1208/S12248-008-9043-6

1 reference

Dimensions Publication ID

15 September 2017

0 references

1 reference

15 September 2017

PubMed publication ID

18607760

1 reference